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HIV-1 mutational escape from a suppressive epitope-specific T-cell response has 
been well described. Analysis of HLA allele associated HIV polymorphism in 
population-based studies (n>800) suggests that HIV may also adapt to favour 
induction of certain epitopes that actively enhance viral replication. We therefore 
sought to investigate the presence and functionality of the HLA-restricted T-cell 
responses driving one such adaptation identified by the genetic analysis (Nef 
D108E in the HLA-C*0702 restricted Nef KY11 epitope).  
 
Cryopreserved PBMC samples from 32 HIV-infected patients with HLA-C*0702 
allele were assayed for IFN-γ production upon stimulation with the adapted and 
non-adapted (‘wild type’) KY11 peptides by ELISpot assay. The functional avidity 
of wild type and variant-specific T-cell directed responses were compared using 
serial peptide dilutions. Autologous epitope sequences were determined from 
contemporaneous plasma samples in patients with detectable HIV viral load 
(n=4). CTL killing of peptide-pulsed EBV transformed B-cells was determined 
using the Chromium release assay.  
 
IFN-γ was detected in PBMC samples from all patients after stimulation with anti-
CD3 or CEF. IFN-γ responses to the wild type or adapted KY11 epitopes were 
detected in 13 patients. The adapted epitope induced IFN-γ responses in 11 
HLA-C*0702 patients (median-500, range 150-1110 spots/million cells). In 3 
samples from 2 cases, the adapted peptide-specific response had greater 
functional avidity than the wild type peptide. Autologous sequence contained the 
D108E adaptation in 1 patient who concurrently demonstrated IFN-γ responses. 
In initial assessments of T-cell killing, HLA-C*0702 B-cells pulsed with wild type 
peptide were killed more readily by adapted peptide CTLs than wild type peptide 
CTLs.  
 
Despite modest levels of epitope-specific IFN-γ responses overall in this 
treatment-experienced patient group, HLA-restricted responses against an HLA-
adapted epitope were demonstrable, including with higher avidity than the wild 
type form in 3 samples, suggesting a functional basis for adaptation driving 
creation of epitopes. In addition, preliminary data on CTL killing suggests lesser 
cytolytic activity of the variant specific T-cell response would favour persistence 
of the adapted virus. These data support the possibility of HIV adapting to 
actively exploit rather than simply evade T-cell responses and have implications 
for epitope inclusion criteria in HIV vaccine design. 
 
